Zylox-tonbridge Medical Technology Co., Ltd. Class H · HKEX:2190
Zylox-tonbridge Medical Technology Co., Ltd. Class H — H1 2025 Earnings Presentation
30 slides from Zylox-tonbridge Medical Technology Co., Ltd. Class H's earnings presentation, August 2025
Slide 1: Zylox-Tonbridge 2025 Interim Results Presentation
Zylox-Tonbridge（2190.HK） 2025 Interim Results Presentation August 2025 1
Slide 2: Disclaimer
Disclaimer This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase
Slide 3: Leading Player in Neuro- and Peripheral Vascular Interventional Medical Device Market in China
Leading Player in Neuro- and Peripheral Vascular Interventional Medical Device Market in China Neuro- Vascular Peripheral Neurovascular vascular closure vascular Intervention Aging Trend 73 Approved & Candidates 50 NMPA approved Vascular Peripheral Intervention vascular Industry Intervention Transfo
Slide 4: Business Highlights
Business Highlights Rapid Revenue & Profit Growth Business Progress 31.7% - First Cash Dividend at 32.1% Payout Ratio 482.0 - First HK-listed 18A High-Value Medical Device Co. 366.0 176.4 With "B" Suffix Removed 46.2% 120.6 - Buyback Ceiling Raised to HK$650 Million 76.0% Global Expansion 25.0% 304.
Slide 5: Financial Highlights
Financial Highlights 5
Slide 6: Product Portfolio and Commercialization Drive Rapid Growth and Profitability
Product Portfolio and Commercialization Drive Rapid Growth and Profitability Rapid Revenue Growth Since Net Profit / (Loss ) 2 Commercialization1 (in RMB million) (in RMB million) Gross 75.6% 72.9% 71.6% 71.3% 71.2% Net 12.8% 18.8% 25.1% Profit Profit Margin： Margin： 782.5 252.4 527.8 31.7% 482.0 12
Slide 7: Neurovascular - Steady Revenue Growth
Neurovascular - Steady Revenue Growth Revenue of Neurovascular Products Main Source of Revenue (in RMB million) % of Revenue : 69.9% 72.3% 67.5% 66.5% 63.2% Kylin SilverSnake Flow Diverter Intracranial Support Catheter 528.5 381.8 25.0% 304.5 Phoenix Thrombite Baiju Detachable Coil Clot Intracranial
Slide 8: Peripheral-vascular - Rapid Revenue Growth
Peripheral-vascular - Rapid Revenue Growth Revenue of Peripheral-vascular Products Main Source of Revenue (in RMB million) Drug Coated Retrievable PTA Balloon Inferior Vena % of Revenue : 30.1% 27.4% 32.3% 33.0% 36.6% Catheter Cava Filter 252.4 176.4 46.2% 144.7 Endovenous Snare PTA Balloon Catheter
Slide 9: Increased Operational Efficiency in Line with Business Development
Increased Operational Efficiency in Line with Business Development Selling and Distribution Expenses R&D Expenses Administrative Expenses % of Revenue % of Revenue % of Revenue 69.9% 49.5% ↓4.2% ↓2.5% 41.9% ↓0.3% 31.0% 32.7% 29.8% 27.7% 22.3% 21.9% 25.2% 21.6% 17.7% 11.6% 11.9% 11.6% 2022A 2023A 202
Slide 10: Sufficient Cash and Efficient Operations to Support Rapid Growth
Sufficient Cash and Efficient Operations to Support Rapid Growth in the Coming Years Cash From Operating 2025H1 Cash Status Trade Receivables Turnover Activities (in RMB million) (in RMB million) (Turnover Days ) 2,510 2,531 154 104 154 0.8 0.6 0.7 2023 2024 2025H1 2024H1 2025H1 2024A 2025H1 (17) (8
Slide 11: Sales and Marketing
Sales and Marketing 11
Slide 12: Policy Inflection Point for Med Devices in H1
Policy Inflection Point for Med Devices in H1 Comprehensive Support for High-Value Medical Devices • NMPA Issues Measures on Optimizing Full- Boost High-Value Medical Lifecycle Supervision to Support High-Value Devices Innovation & Medical Device Innovation & Development Global Edge • Key Focus Area
Slide 13: Key VBPs: Winning Bids & Implementation (2022-2025)
Key VBPs: Winning Bids & Implementation (2022-2025) • Nearly Full-Scale Winning Bids, • Intracranial Support • Flow Diverter:Won in Group B, • Market Share Increased Catheter: Group A Top- Highest Domestic Market Share First Rule 2%→10%+ Ranked Bid Winner • Post-Procurement: PTA • Intracranial PTA b
Slide 14: Smooth VBP Renewal with Moderate Price Reductions
Smooth VBP Renewal with Moderate Price Reductions Hebei Suture-mediated Closure System Jiangsu Coil Renewal Hebei Snare Kit Renewal Renewal 8% Decrease1 10% Decrease2 12% Decrease2 Notes: 1.Suture-mediated Closure System (not in prior round): vs prior avg price 2.Coils & Snare Kit renewals vs.
Slide 15: Peripheral Vascular Intervention: Global Footprint, Full Portfolio Unleashed
Peripheral Vascular Intervention: Global Footprint, Full Portfolio Unleashed Global Dialogue: Building a Two-Way Academic Exchange Platform Matrix Synergy · Breakthrough Innovation • Strengthen Domestic Leadership • Expand Share with Mature Products • New Products Fuel Incremental Growth • Seize VBP
Slide 16: Neurovascular Intervention Business: Global Reach, Multi-Dimensional Growth
Neurovascular Intervention Business : Global Reach, Multi-Dimensional Growth Global Stage: Sino-Foreign Academic Synergy & Technique Integration Reputation Fission · Increment Acceleration • Tier-1 Leadership Solidified • Multiplier Effect Driven by Reputation • Higher Market Share for Mature Produc
Slide 17: Vast Global Market, We Accelerate Global Expansion
Vast Global Market, We Accelerate Global Expansion 12-15% • 22 Products Commercialized in 27 Countries • 7 of Top 10 Global Markets Covered ~$10 Billion • 31+ Products Under Registration in 23 Countries/Regions • Europe Deeper, Emerging Markets Unlocked Global Peripheral Intervention Market China Pe
Slide 18: Product Information
HER (OUR mor ATION
Slide 19: Peripheral-Vascular and Neurovascular Interventional Portfolio
Lay out 73 Products and Candidates, of which 50 have been Commercially Launched in China Peripheral-Vascular Interventional and Neurovascular Interventional Portfolio Vascular Closure Devices Portfolio Intracrania Carotid Hemodi Peripheral Vascular Intracranial Intracranial Hemorrhagic Intracranial
Slide 20: Peripheral Future Product: China's Only Large-Caliber Aspiration Catheter
Peripheral Future Product : China's Only Large-Caliber Aspiration Catheter China's Only Large-Cal Aspiration Heavy-Load Thrombus Buster Catheter(Pending Approval) China's Only 12F-18F Large-Caliber Aspiration Catheter, Exclusive Flared Tip Design, 3.5X Higher Aspiration Flow Tactile Handle Tactile F
Slide 21: Peripheral Future Product: New Arterial Product Portfolio Ready for Launch
Peripheral Future Product : New Arterial Product Portfolio Ready for Launch Specialized Balloon Lower Extremity Artery Stent ◼ Challenge: High Calcification (≥50%)in Leg ◼ Multi-spot Stent: Dual-Layer, Anti-Jump, Arteries, High Difficulty Short Support— China No Commercial Product. ◼ Tech Breakthrou
Slide 22: Neuro Future Product: Embolization Assist Stent
Neuro Future Product :Embolization Assist Stent Embolization Assist Stent (Pending Approval) Indication - Intracranial Hemorrhagic Stroke: Coiling-Assisted Surgical Treatment for Complex/Wide-Neck Aneurysms. - Epidemiology: 4M New Strokes/Yr (20% Hemorrhagic); 40% of Aneurysms Are Wide-Necked. Produ
Slide 23: Neuro Future Product: Solving Wide-Neck Bifurcation Aneurysms
Neuro Future Product :Solving Wide-Neck Bifurcation Aneurysms Self-expandable Recognized Treatment Challenge Aneurysm Embolization Device - Ideal for Wide-Neck Bifurcation Aneurysms. Bifurcation aneurysms(40-60% of intracranial cases) - Complex Shapes, Turbulent Flow, High Rupture Risk & Challenging
Slide 24: Prospects
9 WaNiz NF ZYLOX-TONBRIDGE
Slide 25: Development Strategy: VBPs + International Expansion + Innovation
Development Strategy : VBPs + International Expansion + Innovation Leveraging a comprehensive product portfolio Utilize VBPs to expand market share VBPs Global Growth: Organic & Investment + Harness Product Strengths to Unlock Global Lean Addressable Market Production Global High- Innovation-Driven
Slide 26: Financial Reports
Financial Reports 26
Slide 27: Consolidated Statements of Profit or Loss
Consolidated Statements of Profit or Loss Year ended December 31 Six months ended June 30 % of % of % of % of % of RMB’000 2022 Revenue 2023 Revenue 2024 Revenue 2024 Revenue 2025 Revenue Revenue 334,090 100% 527,754 100% 782,476 100% 365,990 100% 481,969 100% Cost of sales -81,421 -24% -142,766 -27
Slide 28: Consolidated Balance Sheet
Consolidated Balance Sheet Six months ended Year ended December 31 June 30 RMB’000 2022 2023 2024 2025 Non-current assets Property, plant and equipment 290,243 538,540 628,253 632,964 Right-of-use assets 48,136 39,820 37,251 37,126 Intangible assets 9,637 9,686 28,010 30,328 Prepayments and other re
Slide 29: Consolidated Balance Sheet
Consolidated Balance Sheet Six months Year ended December 31 ended June 30 RMB’000 2022 2023 2024 2025 Non-current liabilities Deferred revenue 0 8,674 15,885 16,837 Lease liabilities 7,459 1,859 1,502 2,104 Total non-current liabilities 7,459 10,533 17,387 18,941 Current liabilities Trade and other
Slide 30: Thanks
M4 Wr aNiz OF ‘ZYLOX-TONBRIDGE
Zylox-Tonbridge Medical Technology — H1 2025 Earnings Presentation on 6ix